mersana therapeutics - Search News

William Blair, Mersana Therapeutics

William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation

Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a Outperform recommendation. Analyst Price Forecast Suggests 663.69% Upside As of January 29,

Business Insider · 18h

Mersana Therapeutics initiated with an Outperform at William Blair

William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes

Investing.com on MSN · 16h

William Blair starts Mersana stock with Outperform rating

William Blair initiated coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) with an Outperform rating. The firm's analyst cited the company's potential in the antibody-drug conjugates (ADCs) market as a key reason for the positive outlook.

ETF Daily News · 12d

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Consensus Target Price from Analysts

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the company, Ratings reports.

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on ...

ETF Daily News25d

Mersana Therapeutics’ (MRSN) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report released on Friday morning,RTT News reports. They currently have a $ ...

Nasdaq27d

Mersana Therapeutics Reports Positive Phase 1 Results for Emiltatug Ledadotin in Triple-Negative Breast Cancer

Mersana Therapeutics has reported encouraging preliminary data from the Phase 1 trial of its lead antibody-drug conjugate, emiltatug ledadotin (Emi-Le), which targets B7-H4 in patients with ...

Yahoo Finance28d

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results